Genmab nine-month revenue rises 22% as late-stage pipeline delivers
Genmab reported a 22% revenue increase to $3.24B for the first nine months of 2026, driven by higher royalties and sales of Epkinly. Operating profit dipped to $986M, but adjusted operating profit rose to $1.11B. The company maintained its full-year guidance and announced regulatory approvals and trials for its pipeline. ADRs are down 2% on Thursday.
How this was made
The 30-second read
Why it matters
Revenue beat and strong royalty streams from J&J products indicate robust pipeline execution, while higher operating costs warrant caution.
Market read
First‑report earnings with material revenue growth; actionable for traders monitoring biotech and ADR performance.
What to watch
Operating expense rise of 35% and integration charges could pressure margins in the near term.
Background
Genmab is a Danish biotech with US ADRs (GMAB) focused on oncology antibodies.
Ticker impact
Genmab reported a 22% rise in nine‑month revenue to $3.24 bn, beating prior expectations and maintaining full‑year guidance.
likely modest upside as market prices in the revenue beat and unchanged guidance
The earnings beat is a primary disclosure with material scale; guidance unchanged supports a bullish stance despite the immediate dip.
Market effects
Biotech sector may see broader optimism from Genmab's royalty growth and pipeline progress.
European biotech stocks could benefit as a Danish leader shows strong earnings.
Highlights continued demand for oncology therapies, supporting global pharma sentiment.
Counterpoint
The 2% ADR decline suggests investors may be pricing in higher future expenses or integration costs.
Key entities
- companyGenmab
Danish biotech developing oncology antibodies.
- partnerJohnson & Johnson
Partner whose Darzalex royalties contributed to Genmab's revenue.
